SciELO - Scientific Electronic Library Online

 
vol.33 número3Modelo TOPIC: tareas orientadas a los procesos ambulatorios en el primer nivel de atenciónMeningoencefalitis por Cryptococcus neoformans en adolescente con desnutrición índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Acta Médica Peruana

versión On-line ISSN 1728-5917

Resumen

TERASHIMA, Angélica  y  MARCOS, Luis A. Failure of single-dose triclabendazole in the therapy of human fasciolasis. Acta méd. Peru [online]. 2016, vol.33, n.3, pp.228-231. ISSN 1728-5917.

Human fascioliasis is prevalent in cattle raising areas in Peru. The only effective drug against Fasciola hepatica infections in clinical practice is triclabendazole (TCBZ). However, the occurrence of TCBZ-resistant F. hepatica both in humans and animals has recently been reported in Peru. This issue was previously suspected, due to treatment failure (presence of Fasciola eggs after treatment) in some patients receiving a single dose of TCBZ. Here, we report 11 of 12 human cases infected by F. hepatica who did not respond to TCBZ administered in a single 10 mg/Kg oral dose. Given these results observed in clinical practice, we recommend the use of at least two doses of TCBZ for human fascioliasis. Nowadays, the treatment for fascioliasis has become an emergent problem from the pharmacological point of view. New therapies against Fasciola are urgently needed

Palabras clave : Fasciola hepatica; Triclabendazole; Resistance; Feces.

        · resumen en Español     · texto en Español     · Español ( pdf )